NCCN Hematologic Malignancies Congress

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia.

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses monoclonal antibodies in plasma cell neoplasms.

The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of CAR T-cell therapy in acute lymphocytic leukemia.

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

In relapsed classical Hodgkin lymphoma, the era of therapies post-brentuximab vedotin is developing rapidly.

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).

Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.

​Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).

​Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

There have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma, and pivotal data for each agent has supported rapid inclusion into the NCCN treatment algorithms.

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

​Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).